Pathologic T3a renal cell carcinoma: a classification in need of further refinement.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Detection of critical transition states in complex diseases based on distance correlation coefficient.PloS one · 2026
   Article
2. Impact of the COVID-19 pandemic on diagnosis of renal cell carcinoma and disease stage at presentation.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024
   Article
3. BIRC6 Modulates the Protein Stability of Axin to Regulate the Growth, Stemness, and Resistance of Renal Cancer Cells via the β-Catenin Pathway.ACS omega · 2024
   Article
4. [Effect of small interfering RNA-mediated BIRC6 silencing on apoptosis and autophagy of renal cancer 786-O cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
   Article

Corrections and comments

• Comment on
  Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear-cell renal cell carcinoma.2019

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.